| Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma S Gooding, N Ansari-Pour, F Towfic, M Ortiz Estévez, PP Chamberlain, ... Blood, The Journal of the American Society of Hematology 137 (2), 232-237, 2021 | 106 | 2021 |
| Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia SA Fisher, SJ Brunskill, C Doree, S Gooding, O Chowdhury, DJ Roberts Cochrane Database of Systematic Reviews, 2013 | 76 | 2013 |
| Oral deferiprone for iron chelation in people with thalassaemia SA Fisher, SJ Brunskill, C Doree, O Chowdhury, S Gooding, DJ Roberts Cochrane Database of Systematic Reviews, 2013 | 65 | 2013 |
| Mycobacterium tuberculosis-Specific Cellular Immune Profiles Suggest Bacillary Persistence Decades after Spontaneous Cure in Untreated Tuberculosis KA Millington, S Gooding, TSC Hinks, DJM Reynolds, A Lalvani The Journal of infectious diseases 202 (11), 1685-16849, 2010 | 64 | 2010 |
| Hepcidin is regulated by promoter-associated histone acetylation and HDAC3 SR Pasricha, PJ Lim, TL Duarte, C Casu, D Oosterhuis, ... Nature communications 8 (1), 403, 2017 | 59 | 2017 |
| Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease S Gooding, SWZ Olechnowicz, EV Morris, AE Armitage, J Arezes, J Frost, ... Nature communications 10 (1), 4533, 2019 | 47 | 2019 |
| Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies AO Khan, A Rodriguez-Romera, JS Reyat, AA Olijnik, M Colombo, ... Cancer discovery 13 (2), 364-385, 2023 | 37 | 2023 |
| New approaches to targeting the bone marrow microenvironment in multiple myeloma S Gooding, CM Edwards Current opinion in pharmacology 28, 43-49, 2016 | 35 | 2016 |
| Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice S Gooding, O Chowdhury, T Hinks, L Richeldi, M Losi, K Ewer, ... Journal of Infection 54 (3), e169-e174, 2007 | 33 | 2007 |
| Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders C Anzilotti, AK Kienzler, E Lopez-Granados, S Gooding, B Davies, ... Journal of Allergy and Clinical Immunology 136 (2), 487-490. e2, 2015 | 23 | 2015 |
| COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma K Ramasamy, R Sadler, S Jeans, S Varghese, A Turner, J Larham, ... British Journal of Haematology 196 (1), 95-98, 2022 | 16 | 2022 |
| MicroRNA expression in chronic lymphocytic leukaemia CH Lawrie, E Ballabio, OJ Dyar, M Jones, R Ventura, J Chi, D Tramonti, ... British journal of haematology 147 (3), 398-402, 2009 | 16 | 2009 |
| Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response K Ramasamy, R Sadler, S Jeans, P Weeden, S Varghese, A Turner, ... British Journal of Haematology 197 (3), 293-301, 2022 | 15 | 2022 |
| Managing multiple myeloma in the over 70s: a review AJ King, S Gooding, K Ramasamy Maturitas 80 (2), 148-154, 2015 | 15 | 2015 |
| Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment SWZ Olechnowicz, MM Weivoda, ST Lwin, SK Leung, S Gooding, ... Scientific reports 9 (1), 14189, 2019 | 14 | 2019 |
| Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect TA Eyre, S Gooding, I Patel, N Moore, C Hatton, GP Collins International journal of hematology 99, 798-800, 2014 | 13 | 2014 |
| Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma N Ansari-Pour, M Samur, E Flynt, S Gooding, F Towfic, N Stong, ... Blood 141 (6), 620-633, 2023 | 11 | 2023 |
| Double relapsed and/or refractory multiple myeloma: clinical outcomes and real world healthcare costs S Gooding, IJ Lau, M Sheikh, P Roberts, J Wong, E Dickens, A Bullement, ... PLoS One 10 (9), e0136207, 2015 | 11 | 2015 |
| Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma P Sudha, A Ahsan, C Ashby, T Kausar, A Khera, MH Kazeroun, CC Hsu, ... Clinical Cancer Research 28 (13), 2854-2864, 2022 | 10 | 2022 |
| Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma S Gooding, N Ansari-Pour, M Kazeroun, K Karagoz, A Polonskaia, ... Blood, The Journal of the American Society of Hematology 140 (16), 1816-1821, 2022 | 8 | 2022 |
